Candel Therapeutics Inc (CADL)
8.49
-0.24
(-2.75%)
USD |
NASDAQ |
Jan 10, 12:47
Candel Therapeutics SG&A Expense (Quarterly): 3.341M for Sept. 30, 2024
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Pfizer Inc | 3.244B |
| AnaptysBio Inc | 10.56M |
| Bristol-Myers Squibb Co | 1.983B |
| Inovio Pharmaceuticals Inc | 8.614M |
| NovaBay Pharmaceuticals Inc | 2.65M |